#Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic #Steatohepatitis Without Fibrosis Worsening

http://www.gastrojournal.org/article/S0016-5085(16)00140-2/abstract?referrer=https://www.ncbi.nlm.nih.gov/pubmed?term=+Gastroenterology+%255BJour%255D+AND+2016+%255Bpdat%255D+AND+Ratziu+V%255Bfirst+author%255D&cmd=det

A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH. However, the predefined end point was not met in the intention to treat population. Elafibranor was well tolerated and improved patients’ cardiometabolic risk profile. ClinicalTrials.gov number: NCT01694849.

Rebaudioside affords hepatoprotection ameliorating sugar sweetened beverage- induced nonalcoholic #steatohepatitis
https://2medical.news/2020/05/22/rebaudioside-affords-hepatoprotection-ameliorating-sugar-sweetened-beverage-induced-nonalcoholic-steatohepatitis/

Sugar-sweetened beverage consumption is a known independent risk factor for nonalcoholic steatohepatitis (NASH). Non-caloric sweeteners (NCS) are food additives providing sweetness without calories and are considered safe and/or not metabolized by the liver. The potential role of newer NCS in the regulation of NASH, however, remain unknown. Our study aimed to determine the impact of newer NCS including Rebaudioside A and sucralose on NASH using …

A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis
https://2medical.news/2020/11/18/a-placebo-controlled-trial-of-subcutaneous-semaglutide-in-nonalcoholic-steatohepatitis/

Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.. ..In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to receive semaglutide at a dose of 0.1 mg (80 patients), …

#Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis
https://2medical.news/2021/01/12/renal-failure-is-associated-with-increased-mortality-and-hospital-utilization-in-patients-admitted-with-nonalcoholic-steatohepatitis/

We aimed to investigate the mortality and hospital utilization outcomes of hospitalized nonalcoholic steatohepatitis (NASH) patients with and without kidney failure in a nationwide cohort.. ..The overall sample included 7,135,090 patients. Among 6855 patients admitted for NASH, 598 or 8.7% had comorbid kidney failure. After multivariate regression analysis, NASH patients with renal failure had increased in-hospital mortality [odds ratio=28.72, 95% confidence interval (CI): 8.99-91.73], length …

XCR1+ type 1 conventional #dendritic cells drive liver pathology in non-alcoholic #steatohepatitis

https://2medical.news/2021/05/21/xcr1-type-1-conventional-dendritic-cells-drive-liver-pathology-in-non-alcoholic-steatohepatitis/

Multi-omic network analysis identified #betacellulin as a novel target of #omega-3 fatty acid attenuation of western diet-induced nonalcoholic #steatohepatitis

https://2medical.news/2023/11/24/multi-omic-network-analysis-identified-betacellulin-as-a-novel-target-of-omega-3-fatty-acid-attenuation-of-western-diet-induced-nonalcoholic-steatohepatitis/